6Z7M

N-TERMINAL BROMODOMAIN OF HUMAN BRD4 (3R,4R)-N-cyclohexyl-4-((3-methyl-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl)amino)piperidine-3-carboxamide

これはPDB形式変換不可エントリーです。

6Z7M の概要

• エントリーDOI: 10.2210/pdb6z7m/pdb
• 関連するPDBエントリー: 6Z7L
• 分子名称: Bromodomain-containing protein 4, (3R,4R)-N-cyclohexyl-4-((3-methyl-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl)amino)piperidine-3-carboxamide (3 entities in total)
• 機能のキーワード: inhibitor, histone, epigenetic reader, bromodomain, brd4, bromodomain containing protein 4, antagonist, transcription
• 由来する生物種: Homo sapiens (Human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 15482.87

構造登録者

Chung, C. (登録日: 2020-05-31, 公開日: 2020-07-29, 最終更新日: 2024-05-01)

主引用文献

Watson, R.J.,Bamborough, P.,Barnett, H.,Chung, C.W.,Davis, R.,Gordon, L.,Grandi, P.,Petretich, M.,Phillipou, A.,Prinjha, R.K.,Rioja, I.,Soden, P.,Werner, T.,Demont, E.H.
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
J.Med.Chem., 63:9045-9069, 2020

PubMed Abstract: Pan-bromodomain and extra terminal (BET) inhibitors interact equipotently with all eight bromodomains of the BET family of proteins. They have shown profound efficacy in vitro and in vivo in oncology and immunomodulatory models, and a number of them are currently in clinical trials where significant safety signals have been reported. It is therefore important to understand the functional contribution of each bromodomain to assess the opportunity to tease apart efficacy and toxicity. This article discloses the in vitro and cellular activity profiles of GSK789, a potent, cell-permeable, and highly selective inhibitor of the first bromodomains of the BET family.

PubMed: 32691589
DOI: 10.1021/acs.jmedchem.0c00614

実験手法

X-RAY DIFFRACTION (1.26 Å)